Clinical Trial Update: Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing Erlotinib 100 mg daily to Gefitinib 250 mg daily in EGFR-mutant non-small cell lung cancer; the document provides a trial update with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Advanced Stage Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN